FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 07/2024 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 07/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of June 2024 we identified the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding reached EUR 22,529m
• Biotech received 52% of the total investment volume (EUR 11,810m) with oncology being the leading indication (26%)
• In July Element Biosciences secures the highest transaction volume with EUR 258m, followed by Cardurion with EUR 242m and Beacon Therapeutics with EUR 158m
• ARCH Venture Partners (United States) is the most active investor (by deal volume), followed by RA Capital Management (United States) and F-Prime Capital (United States)

To access the full report, please click here.